- Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
-
Han SJ, Kim HS, Kim KI, Whang SM, Hong KS, Lee WK, Lee SH
- KMID: 1094268
- J Korean Med Sci.
- 2011 Jul;26(7):945-950.
- doi: 10.3346/jkms.2011.26.7.945
Although the incidence of bleeding complications during extracorporeal membrane oxygenator (ECMO) support has decreased in various trials, bleeding is still the most fatal complication. We investigated the ideal dosage and... -
- CITED
-
- Close
- SHARE
-
- Close
- Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients
-
Cho SM, Lee KY, Choi JR, Lee KA
- KMID: 2374082
- Yonsei Med J.
- 2016 May;57(3):635-640.
- doi: 10.3349/ymj.2016.57.3.635
PURPOSE: The genes for cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) have been identified as important genetic determinants of warfarin dosing and have been... -
- CITED
-
- Close
- SHARE
-
- Close
- The use of Low Molecular Weight Heparin to Predict Clinical Outcome in Patients with Unstable Angina That Had Undergone Percutaneous Coronary Intervention
-
Hong YJ, Jeong MH, Lee SH, Park OY, Kim JH, Kim W, Rhew JY, Ahn YK, Cho JG, Park JC, Suh SP, Ahn BH, Kim SH, Kang JC
- KMID: 759656
- Korean J Intern Med.
- 2003 Sep;18(3):167-173.
BACKGROUND: Antithrombotic therapy with heparin reduces the rate of ischemic events in patients with acute coronary syndrome. Low-molecular-weight heparin, given subcutaneously twice daily, has a more predictable anticoagulant effect than... -
- CITED
-
- Close
- SHARE
-
- Close
